ViraxImmune™ Assay for ME/CFS
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
DevelopmentActive; In clinical validation
Key Facts
Indication
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Phase
Development
Status
Active; In clinical validation
Company
About Virax Biolabs
Virax Biolabs is pioneering immune profiling through its ViraxImmune™ platform, which utilizes peptide pools for T cell stimulation and analysis. The company is advancing a novel portfolio of FluoroSpot T cell diagnostics towards regulatory submission, with key partnerships including Emory University for clinical studies and an upcoming FDA pre-submission meeting. Their mission is to translate immunological insights into actionable diagnostics for complex, post-viral conditions, aiming to improve global health outcomes.
View full company profileTherapeutic Areas
Other Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Drugs
| Drug | Company | Phase |
|---|---|---|
| PAX-101 (IV suramin) | PaxMedica | Phase 2 |